Karen Jimenez, MD
Internal Medicine · Mobile, ALNPI 1659395341
Payments from drug & device makers
Across 164 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$629
- AstraZeneca$625
- Bayer$308
- Lilly USA, LLC$289
- AbbVie$263
- Pfizer$144
- plus $723 from 21 others
What the payments were for
- Food & beverage$2,982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $629 |
| AstraZeneca | 19 | $625 |
| Bayer | 16 | $308 |
| Lilly USA, LLC | 16 | $289 |
| AbbVie(2 entities) | 17 | $263 |
| Pfizer | 9 | $144 |
| GSK | 7 | $114 |
| Exact Sciences | 5 | $77 |
| Philips North America LLC | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Amgen | 3 | $48 |
| Merck | 3 | $46 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $30 |
| SK Life Science, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| BD | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,982 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $118,007 |
| MounjaroTirzepatide | 60 | $65,008 |
| FarxigaDapagliflozin Propanediol | 67 | $63,695 |
| EliquisApixaban | 175 | $59,921 |
| JardianceEmpagliflozin | 93 | $50,349 |
| RexultiBrexpiprazole | 53 | $19,629 |
| LinzessLinaclotide | 17 | $19,409 |
| XareltoRivaroxaban | 52 | $17,027 |
| TradjentaLinagliptin | 19 | $14,560 |
| JanuviaSitagliptin Phosphate | 51 | $7,547 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,523 |
| Atorvastatin Calcium | 703 | $5,095 |
| Amlodipine Besylate | 672 | $3,364 |
| Levothyroxine Sodium | 380 | $3,100 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $629 | $118,00779 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $15 | $71,432123 claims |
| Lilly USA, LLCMounjaro | $289 | $65,00860 claims |
| AstraZenecaFarxiga | $625 | $63,69567 claims |
| PfizerEliquis | $144 | $59,921175 claims |
| AbbVieLinzess, Synthroid | $263 | $20,97032 claims |
| MerckJanuvia | $46 | $7,54751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Harry StuddardMobile$12.9M
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Thomas GarthMobile$48K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.